Vir Biotechnology Inc (VIR)

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker VIR. The company focuses on discovering and developing therapies aimed at preventing and treating serious infectious diseases in the United States and abroad. Its clinical pipeline includes investigational programs for hepatitis delta virus and certain solid tumors, while its preclinical work covers areas such as influenza A and B antibodies, antibody-drug conjugates, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T-cell engagers for solid tumors. Vir Biotechnology also maintains multiple research, collaboration, and license agreements with partners including Astellas, Norgine, the Gates Foundation, Brii Biosciences, Alnylam Pharmaceuticals, the Institute for Research in Biomedicine, The Rockefeller University, Xencor, and GlaxoSmithKline Biologicals. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Jump directly to the stock analysis sections supported by the latest available data.